Sanofi-Aventist SA’s weight loss medication, Acomplia, which is not available in the United States, has been linked to five deaths and more than 2,000 reports of adverse reactions in the United Kingdom. The drug was rejected by the U.S. Food and Drug Administration (FDA) in June 2006, due to a risk of self harm and suicides, but it was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in London approximately two years ago. Continued
